NASDAQ:XNCR Xencor Q3 2024 Earnings Results & Report $37.09 0.00 (0.00%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$37.10 +0.00 (+0.01%) As of 03:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Xencor beat analyst earnings expectations but missed on revenue in its Q3 2024 results, released November 6, 2024. The company reported EPS of -$0.71 versus the -$0.98 consensus estimate, while revenue of $10.70 million fell short of the $14.59 million estimate by $3.89 million. Revenue decreased 81.9% year over year. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2024Report DateNovember 6, 2024TimeAfter Market ClosesConference Call DateNovember 5, 2024Conference Call6:00 PM ET Xencor EPS ResultsActual EPS-$0.71Consensus EPS -$0.98Beat/MissBeat by +$0.27One Year Ago EPS-$0.40EPS Beat Rate6 of last 8 quartersXencor Revenue ResultsActual Revenue$10.70 millionExpected Revenue$14.59 millionBeat/MissMissed by -$3.89 millionYoY Revenue Growth-81.90%Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Xencor Q3 2024 Earnings FAQ Did Xencor beat earnings estimates for Q3 2024? Xencor (NASDAQ:XNCR) reported earnings of -$0.71 per share for Q3 2024, beating the consensus estimate of -$0.98. The report was announced on Wednesday, November 6, 2024. What was Xencor's revenue for Q3 2024? Xencor reported revenue of $10.70 million for Q3 2024, against a consensus estimate of $14.59 million. Xencor Earnings HeadlinesXencor Insider Sold Shares Worth $3,189,435, According to a Recent SEC FilingNovember 13 at 8:53 AM | marketscreener.comMEarly Arthritis Data Could Be A Big Test For Xencor Stock (XNCR)November 12, 2026 | finance.yahoo.com$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that link expires, it returns to its usual price of $29.97. The content stays the same - plain-English lessons and a handful of proven techniques - only the price changes. Waiting means paying for something you could have gotten for free. | Profits Run (Ad)Xencor Presents Initial Plamotamab Data in Rheumatoid Arthritis at ACR Convergence 2026 and Updates Progress in First-in-Human Study of XmAb657November 9, 2026 | businesswire.comXencor (NASDAQ:XNCR) Stock Rating Raised to "Buy" at Wall Street ZenNovember 7, 2026 | americanbankingnews.comShow Me The Money: Xencor (XNCR) Delivers Triple-Digit Gains, With XENITH-UC Poised For The Next ActNovember 7, 2026 | rttnews.comSee More Xencor Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Xencor? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xencor and other key companies, straight to your email. Email Address About XencorXencor (NASDAQ:XNCR) is a clinical-stage biopharmaceutical company that discovers and develops engineered antibody therapeutics for cancer and autoimmune diseases. The company’s XmAb technology platform modifies antibody structures to create treatments with properties such as enhanced immune-cell activity or the ability to bind to more than one target. Xencor advances its own drug candidates and works with other biopharmaceutical companies through research collaborations and licensing agreements. Its development programs include antibody-based approaches designed to engage immune cells or block disease-related targets. The company is headquartered in Monrovia, California, and its collaborations extend its work with partners beyond the United States. Founded in 1997, Xencor is led by co-founder and Chief Executive Officer Bassil I. Dahiyat, Ph.D. Its focus is on developing and partnering antibody medicines rather than operating as a broad commercial drug manufacturer.View Xencor ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/13Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCerebras Q3 Results: How Much More Proof Does Wall Street Need?Applied Materials Beats and Raises, But Investors Stay Unconvinced3 Power and Grid Stocks That Could Keep Growing Even if AI Spending SlowsYETI Beat on Earnings, But Its Sales Tell a Different Story Upcoming Earnings Walt Disney (11/17/2026)Home Depot (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.